Eur.- Monograph Tablets -0478- !!better!!: European Pharmacopoeia -ph.

: For tablets with break-marks, the efficacy of the mark is assessed by weighing subdivided parts. Not more than one out of 30 parts may fall outside 85% to 115% of the average mass. 4. Mandatory Pharmacopoeial Tests

Monograph 0478 defines tablets as solid preparations containing a single dose of one or more active substances. They are primarily produced by compressing particles but can also be made through extrusion or freeze-drying (oral lyophilisates). This general monograph covers various categories, including: . Gastro-resistant and Modified-release Tablets . Effervescent, Soluble, and Dispersible Tablets . European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

Disclaimer: This article is for informational purposes and does not substitute for consulting the official European Pharmacopoeia (current edition). Always refer to the legally binding Ph. Eur. text for specific acceptance criteria and validation requirements. : For tablets with break-marks, the efficacy of

The document read like a recipe and a contract. Definitions, nomenclature, identity tests, uniformity, dissolution — each heading framed a patient’s expectation. The monograph did not dictate production methods; instead it set measurable thresholds and validated analytical procedures. Complying with it meant a tablet that would behave as intended from factory line to bedside. Gastro-resistant and Modified-release Tablets

The afternoon brought a call from a small generic manufacturer in a neighboring country. They were struggling to meet the assay method as currently stated in 0478 for a hygroscopic active ingredient. Their headspace sampler produced inconsistent results. Elena requested their chromatograms and method validation reports. As she reviewed them, she recognized a pattern where the stated sample preparation left room for moisture uptake that masked assay accuracy. The fix was simple but important: a clarifying note in the monograph to specify dessicant use and sample equilibration steps before weighing. That single editorial addition would save manufacturers thousands in retesting and reduce batch rejections that had no bearing on patient safety.